A study conducted on animals by Mroz et al. demonstrated that a GIP analog, precisely tailored in terms of receptor selectivity, duration of action, and interspecies activity, is more effective in treating obesity than a GIP antagonist [63]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.